Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Xenon Pharmaceuticals Inc. (NASDAQ: XENE).

Full DD Report for XENE

You must become a subscriber to view this report.


Recent News from (NASDAQ: XENE)

Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference
Stock Monitor: Coherus BioSciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Xenon Pharma Inc. (NASDAQ: XENE ), all you need to do is sign up now by clicking the following link www.active-investors.com/registrati...
Source: ACCESSWIRE IA
Date: May, 17 2018 07:10
Xenon Pharma (XENE) Presents XEN1101 Interim Phase 1 Data At 14th Eilat Conference - Slideshow
The following slide deck was published by Xenon Pharmaceuticals in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 16 2018 13:42
Premarket Gainers as of 9:05 am (05/15/2018)
CLWT +29%  on FY result . More news on: Euro Tech Holdings Company Limited, Medigus Ltd, Xenon Pharmaceuticals, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 09:17
Xenon Pharma up 21% premarket on positive XEN1101 data
Thinly traded nano cap Xenon Pharmaceuticals (NASDAQ: XENE ) is up  21%  premarket on light volume in response to its announcement of positive preliminary results from its ongoing Phase 1 study of epilepsy candidate XEN1101. The data were presented at the Eilat Conference on New ...
Source: SeekingAlpha
Date: May, 15 2018 08:03
Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Ezogabine ...
Source: GlobeNewswire
Date: May, 15 2018 06:10
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre-clinical Data Support Selective Nav1.6 Mechanism of...
Source: GlobeNewswire
Date: May, 15 2018 06:05
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference
BURNABY, British Columbia, May 14, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will provide a corporate update and overview of the presentations on its proprietary epilepsy products, XEN1101 and XEN90...
Source: GlobeNewswire
Date: May, 14 2018 16:46
Xenon Pharmaceuticals' (XENE) CEO Simon Pimstone on Q1 2018 Results - Earnings Call Transcript
Xenon Pharmaceuticals, Inc. (XENE) Q1 2018 Earnings Conference Call May 08, 2018, 16:30 ET Executives Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - President and CEO Ian Mortimer - CFO and COO Analysts Stephen Wiley - Stifel Maury Raycroft - Jefferies Pre...
Source: SeekingAlpha
Date: May, 12 2018 11:34
Xenon Pharma beats by $0.27
Xenon Pharma (NASDAQ: XENE ): Q1 EPS of -$0.21 beats by $0.27 . More news on: Xenon Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:11
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Xenon’s novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming  14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018 BURNABY, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc...
Source: GlobeNewswire
Date: May, 08 2018 16:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-176.406.456.556.35259,409
2017-03-108.408.258.408.2026,387
2017-03-098.108.408.457.8707111,828
2017-03-088.408.358.558.3087,809
2017-03-078.208.408.558.1855110,625

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-157,92915,72950.4101Short
2018-08-1416,22036,26744.7239Short
2018-08-1315,15736,25041.8124Short
2018-08-1041,32063,34165.2342Short
2018-08-0966,040134,79048.9947Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XENE.


About Xenon Pharmaceuticals Inc. (NASDAQ: XENE)

Logo for Xenon Pharmaceuticals Inc. (NASDAQ: XENE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $105,314,619 - 05/11/2018
  • Issue and Outstanding: 18,002,499 - 03/02/2018

 


Recent Filings from (NASDAQ: XENE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 18 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018

 

 


Daily Technical Chart for (NASDAQ: XENE)

Daily Technical Chart for (NASDAQ: XENE)


Stay tuned for daily updates and more on (NASDAQ: XENE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: XENE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XENE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of XENE and does not buy, sell, or trade any shares of XENE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/